Please login to the form below

Not currently logged in
Email:
Password:

VTE

This page shows the latest VTE news and features for those working in and with pharma, biotech and healthcare.

AbbVie’s upadacitinib aces phase III trial

AbbVie’s upadacitinib aces phase III trial

Crucially for AbbvVie, there were no cases of venous thromboembolism (VTE) in the 1, 629-patent study, something that was observed in two earlier phase III studies of the drug ... Analysts said the lack of VTEs in the latest study reduced the risk in the

Latest news

More from news
Approximately 3 fully matching, plus 45 partially matching documents found.

Latest Intelligence

  • Modern anticoagulants threaten status quo Modern anticoagulants threaten status quo

    It is indicated for the prevention of VTE after orthopaedic surgery and is administered subcutaneously once daily. ... The drug is also in phase III development for the acute treatment of VTE.

  • Case study: Using avatar technology to reduce VTE

    The programme was endorsed by The Royal Pharmaceutical Society and promoted among VTE Exemplar Centres. ... Evidence from the field suggests pharmacists have been encouraged to pick up the gauntlet of VTE prevention.

  • Go with the flow

    risk. VTE risk assessment has been included as a DH priority in the NHS Operating Framework 2010/11.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

  • NOAC Education: Empowering Stroke Prevention

    Prophylactic anticoagulation is also being explored in conditions such as embolic strokes of undetermined source (ESUS) or when there is a risk of a patient developing venous thromboembolism (VTE).

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
EPG Health

REACH, ENGAGE & MEASURE - Accomplish meaningful HCP engagement via Medthority, our trusted independent medical website. Support education and treatment...

Latest intelligence

How to make an impact at a virtual congress
As hard as congress organisers try, replicating the congress experience on a virtual platform is difficult. Rather than trying to replicate the in-person congress experience, the industry has a real...
Live webinar
China: How pharma can maximize success in this rapidly changing emerging market...
brian smith science of the deal
The science of the deal
Business development is more like child-raising than you might think...

Infographics